We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton, Dickinson (BDX) Beats on Q4 Earnings & Revenues
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, reported fourth-quarter fiscal 2016 earnings of $2.12 per share, which beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter.
At comparable currency-neutral basis, revenues climbed 5.6% to $3.23 billion, marginally better than the Zacks Consensus Estimate of $3.22 billion.
BD Medical revenues grew 7.9% year over year to almost $2.24 billion. The upside came from strong performance by Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units. Results were driven by double-digit growth in China, strength in dispensing and infusion, and sales of safety-engineered products.
BD Lifesciences revenues increased 2.1% from the year-ago quarter to $996 million. The upside came from Diagnostic Systems, Biosciences, research instruments and reagents in the U.S. This was partially offset by declines in Africa.
Geographically, U.S. revenues increased 6.7% to roughly $1.75 billion, while International revenues were up 5.2% on a currency-neutral basis to $1.48 billion.
Guidance
For fiscal 2017, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 4.5% to 5.0%.
Meanwhile, adjusted earnings (on a currency-neutral basis) are expected in the range of $9.62 to $9.72, reflecting year-over-year growth of 12.0% to 13.0%. However after including the estimated unfavorable impact from foreign currency, the company expects adjusted diluted earnings per share between $9.45 and $9.55, which represents growth of approximately 10.0% to 11.0%.
Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 32.9%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 23.14%.
C.R. Bard recorded a stellar one-year return of almost 15.02%. Notably, the company has an impressive long-term expected growth rate of 11.16%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Becton, Dickinson (BDX) Beats on Q4 Earnings & Revenues
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, reported fourth-quarter fiscal 2016 earnings of $2.12 per share, which beat the Zacks Consensus Estimate by 3 cents and increased from $1.94 posted in the year-ago quarter.
At comparable currency-neutral basis, revenues climbed 5.6% to $3.23 billion, marginally better than the Zacks Consensus Estimate of $3.22 billion.
Quarter Details
BD Medical revenues grew 7.9% year over year to almost $2.24 billion. The upside came from strong performance by Medication Management Solutions, Pharmaceutical Systems and Diabetes Care units. Results were driven by double-digit growth in China, strength in dispensing and infusion, and sales of safety-engineered products.
BD Lifesciences revenues increased 2.1% from the year-ago quarter to $996 million. The upside came from Diagnostic Systems, Biosciences, research instruments and reagents in the U.S. This was partially offset by declines in Africa.
Geographically, U.S. revenues increased 6.7% to roughly $1.75 billion, while International revenues were up 5.2% on a currency-neutral basis to $1.48 billion.
Guidance
For fiscal 2017, on a comparable and currency-neutral basis, revenues are anticipated to increase approximately 4.5% to 5.0%.
Meanwhile, adjusted earnings (on a currency-neutral basis) are expected in the range of $9.62 to $9.72, reflecting year-over-year growth of 12.0% to 13.0%. However after including the estimated unfavorable impact from foreign currency, the company expects adjusted diluted earnings per share between $9.45 and $9.55, which represents growth of approximately 10.0% to 11.0%.
BECTON DICKINSO Price, Consensus and EPS Surprise
BECTON DICKINSO Price, Consensus and EPS Surprise | BECTON DICKINSO Quote
Zacks Rank & Key Picks
Currently, Becton, Dickinson carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the same space are Intuitive Surgical Inc. (ISRG - Free Report) , AngioDynamics Inc. (ANGO - Free Report) and C.R. Bard .
Notably, Intuitive Surgical and AngioDynamics sport a Zacks Rank #1 (Strong Buy), while C.R. Bard has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 32.9%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 23.14%.
C.R. Bard recorded a stellar one-year return of almost 15.02%. Notably, the company has an impressive long-term expected growth rate of 11.16%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>